A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients - Wikidata - awgldk - TriplyDB

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

http://www.wikidata.org/entity/Q28546535

about

Correction: A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients Silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation.Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements.

P2860

Q28633296-BFDE9AF6-E051-4D32-9083-EFE42C30FADC Q33597982-09B6B9D8-EADE-42F0-B00E-1C171C0B648A Q39104518-5ABBAA4B-3804-4976-80E3-4D6BA05F3293 Q40126459-1F734A16-E111-4D1A-B14C-DEBBC63F8E92 Q50077257-7E7A801D-6C46-42E5-BFD1-16C3AE6CC3C3

P2860

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

http://www.wikidata.org/entity/Q28546535

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@ast

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@en

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@nl

type

label

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@ast

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@en

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@nl

prefLabel

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@ast

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@en

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@nl

P1433

Q28546535-82A13E0F-7723-4FEB-9ED7-041D29A09AA7

P1476

Q28546535-6DFE83D5-AC1C-4FAE-AA52-337E2523351F

P2093

Q28546535-0BDED964-1ADB-462B-8C65-14E3A003E576

Q28546535-1B847C24-1F6B-4A91-812B-4E5096E8D892

Q28546535-1CB8E9F0-3BC1-4BF1-A459-88E00DE3B8C2

Q28546535-34B52691-E797-43CB-8307-51735F8B4787

Q28546535-4BAF6848-015F-476D-A988-584A750A3373

Q28546535-5BA21D1A-3532-435B-9B8B-B4AF0AD08CBD

Q28546535-7A20970C-D1CC-4497-BE5D-A256F34E6A20

Q28546535-8CBB4D01-DB2A-446D-BF7C-2C7853081A1B

P2860

Q28546535-08223086-2051-4BB7-8F5D-0200768833B8

Q28546535-0E776383-67B7-4454-8EA3-0BB059FCC139

Q28546535-13A28F94-B357-4619-AB6C-6B7D6AE15C2F

Q28546535-3BFF9C3F-2AC0-43E5-B2BC-DC3145503503

Q28546535-3E1B11FD-8280-4B07-9E78-C1C44F681422

Q28546535-446D3F38-5698-4636-9A08-98970B290F24

Q28546535-44798EAE-0C08-4E0D-A4FA-F13934E0F6F4

Q28546535-476420BF-BDD9-4ED0-BB5C-758718618D8A

Q28546535-4D934920-290F-49C4-ACFC-3E9D8DCD439E

Q28546535-50460EBB-5386-45AD-98DF-731788E56A6B

P304

Q28546535-9AE9D97C-1908-46B8-B9A1-7A6B63761FAD

P31

Q28546535-F28A6830-DEA9-4754-9C1B-84FA484A2575

P356

Q28546535-B77D9E85-628B-4E39-B17F-6249DB9C9B04

P407

Q28546535-393EC52F-7317-4B5B-BD4F-0C098CA13AE2

P433

Q28546535-5782946E-7184-4AC8-8F07-CD1BC4A0FEE8

P478

Q28546535-41ADC1D7-9BA0-49C9-A70A-4F3766C8FDA1

P50

Q28546535-243B621F-5AC0-43DB-9007-36A78316CAFA

Q28546535-5C1348E1-10FE-4874-AA40-39840EF453C7

Q28546535-6A204219-E1EF-44FE-BB5B-425FF00BEBEF

Q28546535-7BA13C7F-A8EF-4D61-B4C3-9886D93FFAB7

Q28546535-A09D2790-8550-4D8B-AB6F-FA5F3B57E1B8

P577

Q28546535-AAE765F2-C927-4EC0-9609-32A4DC7D4EAB

P5875

Q28546535-99FB9383-1EF5-4536-949E-8C0E0BBD5F27

P698

Q28546535-086A2E31-6A2D-4653-8DA1-0497B2BEA7F0

P921

Q28546535-15446660-702F-45AA-A09C-3CFDC05D8D29

P932

Q28546535-7A85CF5D-6E62-4A0C-9051-0DFBEE20F2D2

P356

JOURNAL.PONE.0133028

P1433

P1476

A Lead-In with Silibinin Prior ...... epatitis C Coinfected Patients

@en

P2093

Andri Rauch

http://www.w3.org/2001/XMLSchema#string

Beat Müllhaupt

http://www.w3.org/2001/XMLSchema#string

Dominique L Braun

http://www.w3.org/2001/XMLSchema#string

Jan Fehr

http://www.w3.org/2001/XMLSchema#string

Manel Aouri

http://www.w3.org/2001/XMLSchema#string

Nadia Eberhard

http://www.w3.org/2001/XMLSchema#string

Nina Durisch

http://www.w3.org/2001/XMLSchema#string

Rainer Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Telaprevir for retreatment of HCV infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

P304

e0133028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0133028

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Bruno Ledergerber

Alexia Anagnostopoulos

Karin J Metzner

Laurent Arthur Decosterd

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280091265

http://www.w3.org/2001/XMLSchema#string

P698

26176696

http://www.w3.org/2001/XMLSchema#string

P921

P932

4503454

http://www.w3.org/2001/XMLSchema#string